Generation of allo-restricted cytotoxic T lymphocytes against malignant glioma by artificial antigen-presenting cells

Cancer Letters

Volumn 256, Issue 1, 2007, Pages 128-135

  Lu, Xiao ling ^a   Jiang, Xiao bing ^b   Liu, Ru en ^c   Zhang, Fang cheng ^b   Zhao, Hong yang ^b  

^a FUDAN UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

Allo restricted cytotoxic T lymphocytes (allo restricted CTLs); Artificial antigen presenting cells (aAPCs); Interleukin 13 receptor 2 (IL 13R 2); Malignant glioma

Indexed keywords

CD28 ANTIBODY; CD83 ANTIGEN; CELL ANTIBODY; HLA A2 ANTIGEN; HLA ANTIBODY; INTERLEUKIN 13 RECEPTOR ALPHA2; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; CELL SIZE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG INHIBITION; ENZYME LINKED IMMUNOSPOT ASSAY; GLIOBLASTOMA; GLIOMA CELL; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT;

ANTIGEN-PRESENTING CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; GLIOMA; HLA-A2 ANTIGEN; HUMANS; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 34548240534     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.07.015     Document Type: Article

References (36)

1. Zinkernagel R.M., and Doherty P.C. MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv. Immunol. 27 (1979) 51-177
2. Germain R.N., and Margulies D.H. The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol. 11 (1993) 403-450
3. Rammensee H.G., and Bevan M.J. Evidence from in vitro studies that tolerance to self antigens is MHC-restricted. Nature 308 (1984) 741-744
4. Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86 (1995) 2041-2050
5. Childs R., Chernoff A., Contentin N., et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheralblood stem-cell transplantation. N. Engl. J. Med. 343 (2000) 750-758
6. Sadovnikova E., and Stauss H.J. Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 93 (1996) 13114-13118
7. Sadovnikova E., Jopling L.A., Soo K.S., et al. Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur. J. Immunol. 28 (1998) 193-200
8. Dutoit V., Guillaume P., Romero P., et al. Functional analysis of HLA-A*0201/Melan-A peptide multimer+CD8+ T cells isolated from an HLA-A*0201-donor: exploring tumor antigen allorestricted recognition. Cancer Immun. 2 (2002) 7
9. Mutis T., Blokland E., Kester M., et al. Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation. Blood 100 (2002) 547-552
10. Amrolia P.J., Reid S.D., Gao L., et al. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood 101 (2003) 1007-1014
11. Savage P., Gao L., Vento K., et al. Use of B cell bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood 103 (2004) 4613-4615
12. Murata T., Obiri N.I., Debinski W., et al. Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem. Biophys. Res. Commun. 238 (1997) 90-94
13. Mintz A., Gibo D.M., Slagle-Webb B., et al. IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia 4 (2002) 388-399
14. Husain S.R., and Puri R.K. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J. Neurooncol. 65 (2003) 37-48
15. Okano F., Storkus W.J., Chambers W.H., et al. Identification of a novel HLA-A*0201 restricted cytotoxic T lymphocyte epitope in a human glioma associated antigen, interleukin-13 receptor 2 chain. Clin. Cancer Res. 8 (2002) 2851-2855
16. Parker K.C., Bednarek M.A., Hull L.K., et al. Sequence motifs important for peptide binding to the human MHC class I molecule HLA-A2. J. Immunol. 149 (1992) 3580-3587
17. Altman J.D., Moss P.A., Goulder P.J., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274 (1996) 94-96
18. Molldrem J.J., Lee P.P., Wang C., et al. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 59 (1999) 2675-2681
19. Rees W., Bender J., Teague T.K., et al. An inverse relationship between T cell receptor affinity and antigen dose during CD4+ T cell responses in vivo and in vitro. Proc. Natl. Acad. Sci. USA 96 (1999) 9781-9786
20. Qian L., and Qian G.X. In vivo CTL immunity can be elicited by OVA-linker-β2m fusion protein. Acta Biochim. Biophys Sin. 34 (2002) 547-552
21. T Maziarz R., Fraser J., Srominger J.L., et al. The human HLA-specific monoclonal antibody W6/32 recognizes a discontinuous epitope within the α2 domain of murine H-2Db. Immunogenetics 249 (1986) 206-208
22. Wen P.Y., and Kesari S. Malignant gliomas. Curr. Neurol. Neurosci. 4 (2004) 218-227
23. Barba D., Saris S.C., Holder C., et al. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J. Neurosurg. 70 (1989) 175-182
24. Merchant R.E., Grant A.J., Merchant L.H., et al. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer (Phila.) 62 (1988) 665-671
25. Plautz G.E., Miller D.W., Barnett G.H., et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin. Cancer Res. 6 (2000) 2209-2218
26. Sankhla S.K., Nadkarni J.S., and Bhagwati S.N. Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors. J. Neurooncol. 27 (1996) 133-140
27. Lillehei K.O., Mitchell D.H., Johnson S.D., et al. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 28 (1991) 16-23
28. Quattrocchi K.B., Miller C.H., Cush S., et al. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J. Neurooncol. 45 (1999) 141-157
29. Heimberger A.B., Archer G.E., Crotty L.E., et al. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 50 (2002) 158-164
30. Glick R.P., Lichtor T., Mogharbel A., Taylor C.A., et al. Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma. Neurosurgery 41 (1997) 898-906
31. Glick R.P., Lichtor T., de Zoeten E., et al. Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2. Neurosurgery 45 (1999) 867-874
32. Sampson J.H., Archer G.E., Ashley D.M., et al. cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc. Natl. Acad. Sci. USA 93 (1996) 10399-10404
33. Salgaller M.L., Lodge P.A., Mclean J.G., et al. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate 35 (1998) 144-151
34. Walunas T.L., Bakker C.Y., and Bluestone J.A. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 183 (1996) 2541-2550
35. Walunas T.L., Lenschow D.J., Bakker C.Y., et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1 (1994) 405-413
36. Hirano N., Butler M.O., Xia Z.N., et al. Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood 107 (2006) 1528-1536